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Extrauterine and extraovarian endometrial stromal sarcomas (ESSs) without endometriosis are
extremely rare. A 57-year-old woman had a pelvic mass. Twenty years previously, she had undergone total
hysterectomyand left salpingo-oophorectomy for uterinemyomas.A series of examinations, includingupper
and lower gastrointestinal evaluations, and tumor markers such as cancer antigen (CA)-125, CA 19-9, and
carcinoembryonic antigen were all unremarkable; however, an 18-cm heterogeneous mass with strong
enhancement and many surrounding engorged vessels was present in the pelvic computed tomography
image. Exploratory laparotomy showed a 20-cm gray ﬁrmmass. A complete tumor excisionwas performed.
Microscopic features showed abundant spindle cells and epithelioid-like cells with increased cellularity.
Immunohistochemistrywas strongly positive for CD10, FLI-1, andvimentin;weakly positive for estrogen and
progesterone receptors; and negative for CD117, CD34, HMB45, alpha-inhibin, SMA, and S-100. This favored
the diagnosis of ESS. The right ovary and fallopian tube, omentum, and pelvic lymph nodes were unre-
markable. The patient was treated with 2-year hormone therapy (oral megestrol, 160 mg, taken daily) and
radiation therapy (50.4 Gy, separated by 28 fractions). She has been disease-free for 3 years. Active man-
agement, including complete resection andhormone therapywith/without radiation is beneﬁcial forwomen
with extrauterine and extraovarian ESS.
Copyright  2014, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometrial stromal sarcoma (ESS) is a rare neoplasm that
comprises approximately 0.2% of all uterine malignancies and
approximately 10e15% of all uterine sarcomas.1 Endometrial stro-
mal sarcoma histologically resembles stromal cells during the pro-
liferative phase of the menstrual cycle and displays a characteristic
pattern of myometrial inﬁltration and a rich network of smallts of interest relevant to this
ics and Gynecology, Taipei
g@ym.edu.tw (P.-H. Wang).
ia-PaciﬁcAssociation forGynecologicEnarterioles resembling the spiral arterioles of the secretory endo-
metrium.2 Because endometrial stromal cells are a key component
of ESS, extrauterine and extraovarian ESSs are extremely rare,
especially in women without endometriosis, although ESS is sup-
posed to share some similarities with endometriosis. In this report,
we present a case of extrauterine and extraovarian ESS of the pelvis.
The case was unusual because of the history of total hysterectomy
and absence of associated endometriosis.
Case report
A 57-year-old woman, gravida 2, para 2, had noticed a palpable
mass in the left lower quadrant of the abdomen for months, and
also had complained of frequency and nocturia during this period.
Her past history was unremarkable, except that she had undergonedoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rights reserved.
Fig. 2. A 20 cm  13 cm  11 cm gray ﬁrm tumor with several yellowish necrotic parts.
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uterine myomas 20 years previously. A series of examinations,
which included upper and lower gastrointestinal tract evaluations,
and measurement of the levels of tumor markers such as cancer
antigen (CA)-125 (10.70 U/mL; normal range, <35 U/mL), CA 19-9
(2.54 U/mL; normal range, <35 U/mL), carcinoembryonic antigen
(1.31 ng/mL; normal range, <15 ng/mL) were all unremarkable.
However, magnetic resonance image ﬁndings were positive for an
18-cm heterogeneous solid mass with strong enhancement that
was surrounded by many engorged vessels (Fig. 1). Exploratory
laparotomy was performed with complete removal of the tumor (a
20-cm gray ﬁrm mass) after delicate dissection of the surrounding
tissue, including the omentum and the small intestines. Frozen
pathology favored malignancy. A thorough staging surgery (which
included lymph node sampling) and multiple random biopsies
were performed. The tumor was grossly 20 cm, gray, and ﬁrm. The
cut surface showed multiple yellow necrotic parts (Fig. 2). Micro-
scopic features showed abundant spindle cells and epithelioid-like
cells with increased cellularity. The immunohistochemistry study
(Fig. 3) was strongly positive for CD10, FLI-1, and vimentin; weakly
positive for the estrogen receptor (ER) and progesterone receptor
(PR); and negative for CD117, CD34, HMB45, alpha-inhibin, smooth
muscle actin (SMA), and S-100. Because the other excisionsdwhich
included the right ovary and fallopian tube, omentum, and pelvic
lymph nodesdwere all free of tumor, the ﬁnal surgicopathologic
diagnosis was ESS, 2009 International Federation of Gynecology
and Obstetrics (FIGO) stage IIIA. The patient was treated with 2-
year hormone therapy (oral megestrol, 160 mg, taken daily) and
radiation therapy (50.4 Gy, separated by 28 fractions). She has been
disease-free for 3 years.
Discussion
Endometrial stromal sarcomas are the second most common
uterine sarcoma and are classiﬁed as low-grade ESS or undiffer-
entiated endometrial sarcoma.3 Because ESSs are exclusively
composed of cells resembling those of the endometrial stroma in itsFig. 1. The sagittal T2-weighted fat-suppressed image (4800/110; slice thickness,
5 mm; 256  256) shows a large heterogeneously enhanced mass.proliferative phase,4 extrauterine ESSs are rare. In addition, the
ovary is the primary site in 76% of extrauterine ESS cases, and
extraovarian sites account for the remaining 24%.5,6 This suggests
that our reported case was unusual. In fact, extrauterine and
extraovarian ESSs have been found in many abdominal or pelvic
organs, including the Fallopian tubes, pelvic cavity, colon, appendix,
and retroperitoneum.6 Many ESSs are associated with endometri-
osis or may be associated with prolonged estrogenic stimulation,
tamoxifen treatment, or a history of pelvic irradiation.7 In our pa-
tient, endometriosis could not be identiﬁed in the pathological
review after complete surgical staging, which further demonstrates
the uniqueness of our case.
It is sometimes difﬁcult to make an accurate diagnosis of low-
grade ESS, especially the extrauterine type. Most ESSs of the uterus
are low-grade and display overt endometrial stromal differentiation
and bland nuclear features.3 However, the gross appearance of low-
grade ESS can vary, and it is typically soft, ﬂeshy, bulging, and tan to
yellow without prominent necrosis. By contrast, in our ESS case, the
gross picture showed a gray ﬁrmmass with multiple yellow necrotic
parts. In the microscopic view, low-grade ESSs are typically cellular
and composed of uniform, oval, fusiform to spindle cells that
resemble proliferative endometrial stromal cells with mild nuclear
atypia. The mitotic rate of low-grade ESS is low, often less than 3
mitoticﬁgures (MF)/10 high-powerﬁeld (HPF), as seen in our patient.
An immunohistochemistry evaluation is often used in the
diagnosis of low-grade ESS. Low-grade ESS is typically positive for
CD10, which is the most useful marker.3 However, some studies
have found only focal and weak CD10 positivity in up to 40% of low-
grade ESS, and rare cases have been completely negative for this
marker.8 Desmin, h-caldesmon, and histone deacetylase 8 are
typically negative in pure ESS, although focal staining for desmin
has been found in some patients; this suggests that in the differ-
ential diagnosis between ESS and smooth muscle tumors, h-
caldesmon and histone deacetylase 8 are more speciﬁc and sensi-
tive, compared to desmin.7 Because no single marker is entirely
sensitive or speciﬁc, a panel of immunostains is of the most value in
making an accurate diagnosis, as shown in our ESS case.
Most ESSs express hormone receptors, including the ER and PR
and possibly the androgen receptor (AR); however, these hormone
receptors seem to be heterogeneous among tumors, ranging from a
weak and focal pattern to a strong and diffuse pattern and from 0%
to 95%.7 In general, low-grade ESSs express a high percentage of
positivity for the ER and PR, and different subtypes of ERs and PRs
seem to be valuable in ESSs. Approximately 80% of ESSs express ER-
Fig. 3. Microscopic ﬁndings of the tumor. The sections show spindle and epithelioid features: (A) hematoxylin-eosin stain, 200 magniﬁcation; (B) hematoxylin-eosin stain, 400.
Immunohistochemical staining analyses reveal that the neoplastic cells are immunoreactive to (C) vimentin,400; (D) CD10,400; andweakly stain for (E) estrogen receptor (ER),400.
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(which is involved in apoptosis).9 By contrast, PR-alpha is the
dominant isoform in ESSs; however, in recurrent ESSs, PR-alpha
levels are reduced and PR-beta levels are increased.10
In the management of our patient, some controversial issues
were present. First, it was difﬁcult to provide the 2009 FIGO stage
for this patient because 2009 FIGO stage IIA or IIIA were both
acceptable. The deﬁnition of 2009 FIGO stage II and stage III of
uterine sarcomas is that the tumor extends to the pelvis and in-
vades abdominal tissues, respectively.11 However, the tumor in the
current patient who had a history of total hysterectomy, and the
main tumor grew from the pelvic cavity to the abdominal cavity
(not just protruding into the abdomen) because the infracolic
omentum covered the tumor and the small intestine adhered to the
abdominal part of the tumor. The ﬁnal pathology failed to detect
seeding or tumor invasion of the omentum or other organs. Second,
many prognostic factors in ESSs have been reported previously,
including clinical and pathological factors such as age, race, parity,
menopausal status, stage, tumor size, nuclear atypia, mitotic index,
tumor necrosis, lymphatic space invasion, status of surgical resec-
tion margins, DNA ploidy/proliferation index, and ER, PR, and AR
expression.7 However, all of these factors are based on uterine type-
ESSs. Therefore, the prognostic factors of extrauterine andextraovarian ESS are unknown. We believe that surgery may be the
most important component of treatment for ESSs because the
absence of primary surgery and incomplete cytoreduction have
indeed been shown to be independent prognostic factors.12 As with
uterine ESSs, postoperative adjuvant therapy is debated. Until
recently, evidence of the role of adjuvant radiotherapy in uterine
ESSs had been limited to retrospective noncomparative case series
because no case series has been sufﬁciently large to quantify the
potential beneﬁt of radiotherapy. For example, the European Or-
ganization for Research and Treatment of Cancer Gynaecological
Cancer Group (EORTC CGC) conducted a prospective, randomized
Phase III study to evaluate the effect of postoperative radiation in
FIGO stage I and stage II diseases; the group spent 13 years on the
study and only 30 cases of ESS were included.13 In addition, recent
data from the National Cancer Institute (Bethesda, MD, USA) Sur-
veillance, Epidemiology, and End Results program (SEER) showed
no improvement in overall survival with the addition of radio-
therapy to surgery, although the impact on local tumor control was
not mentioned.14
The role of adjuvant chemotherapy is also conﬂicted because
chemotherapy is used for metastatic disease. The acceptable ﬁrst-
line regimen is a combination of doxorubicin with or without
ifosfamide, although gemcitabine and docetaxel look promising in
Y.-F. Lu et al. / Gynecology and Minimally Invasive Therapy 3 (2014) 19e2222the ﬁrst-line setting. However, this information is based on a study
of leiomyosarcomawith very little information available on the role
of chemotherapy in ESS.7 Therefore, no chemotherapy was pre-
scribed for this patient.
Third, becausemost low-grade ESSs are positive for the ER and PR,
hormone therapy may be an alternative with clear evidence of ESS
responsiveness to hormone therapy; responses to progestins, aro-
matases inhibitors, and gonadotropin releasing hormone agonists
have been reported.15e17 In this ESS case, we treated the patient with
2-year megestrol (160 mg) on a daily basis; this protocol was based
on two small studies15,18 that showed the beneﬁts of using adjuvant
medroxyprogesterone (250 mg) or megestrol (160 mg) on a daily
basis for 2 years. However, patients should be informed of the po-
tential side effects of progestins, including thrombosis and weight
gain.19,20
In conclusion, extrauterine and extraovarian ESSs are extremely
rare; therefore, treatment is often based on experience in managing
uterine ESSs. Complete surgical resection is themain component of a
good outcome.21 The use of postoperative radiotherapy and/or hor-
mone therapy can be guided by the history and condition of the
patient.
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